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mated. Therefore prescriptions causing interaction coming from one ofﬁce should be 
prevented. But prescriptions from different ofﬁces cannot be avoided by the use of 
this isolated solution. Only a comprehensive e-health solution summoning up medica-
tion of a patient from different sources has the potential to improve patient safety. 
There are pharmacologic interactions with different clinical relevance.
PCV10
A META-ANALYSIS OF CARDIOVASCULAR RISK FACTORS: WHICH IS 
THE DIFFERENCE BETWEEN MEN AND WOMEN?
Villasis-Keever MA1, Rendón-Masías ME1, Pineda-Cruz R1, Escamilla-Nuñez A1, 
Mould-Quevedo JF2
1Instituto Mexicano del Seguro Social, Mexico City, Mexico, Mexico, 2Pﬁzer S.A. de C.V., 
México City, Mexico
OBJECTIVES: The aim of this study was to conduct a meta-analysis to identify the 
potential differences of cardiovascular risk factors between men and women in 
primary prevention. METHODS: A systematic review was performed identifying 
prospective cohorts studies in which cardiovascular risk factors were analyzed 
(tobacco use, hypertension, diabetes, obesity and dyslipdemia) associated to the devel-
opment of acute myocardial infarction, angina pectoris or cardiovascular death, and 
in which results were segmented between men and women. The search was done in 
October 2009 in Medline, EMBASE and the Cochrane Collaboration. Two indepen-
dent reviewers identiﬁed the abstracts, selected full articles and extracted the data. 
Relative risk(RR) with 95% conﬁdence intervals (95%CI) were calculated. Random 
effects models were employed in the meta-analyses using Meta-Analyst v.2.0 software. 
A meta-regression was also conducted. RESULTS: From 3,712 studies, 21 cohort 
studies were selected. The number of participants among the trials varied between 
5,000 and 600,000 per study with a follow-up from 5 to 40 years. The meta-analyses 
showed that premenopausal women in comparison to men had a higher risk of having 
cardiovascular event when they have diabetes mellitus (RR 2.79 vs. 2.03), obesity 
(1.62 vs. 1.41), hypercholesterolemia (1.91 vs. 1.49), increase in LDL levels (2.08 vs. 
1.72) or increase in HDL levels (2.22 vs. 1.61); however, men showed higher risk of 
cardiovascular events when they have hypertension (RR 1.771; 95%CI 1.714–1.830 
vs. RR 1.812; 95%CI 1.759–2.305). In addition, women use of contraceptives was 
not a signiﬁcant cardiovascular risk factor. CONCLUSIONS: The majority of cardio-
vascular risk factors seem to be higher in premenopausal women rather than men. 
Preventive programs should include female population in other to avoid a greater 
number of cardiovascular events in the future.
PCV11
IDENTIFYING RISK FACTORS ASSOCIATED WITH DISEASE BURDEN IN 
PATIENTS WITH TYPE II DIABETES AND COMORBID 
CARDIOVASCULAR DISEASE
Nichol MB1, Wu J1, An JJ1, Knight TK1, Priest J2, Cantrell C2
1University of Southern California, Los Angeles, CA, USA, 2GlaxoSmithKline, RTP, NC, USA
OBJECTIVES: To evaluate 1) use of diabetes and cardiovascular medications; 2) the 
associations of medication compliance with disease burden. METHODS: California 
Medicaid administrative data (2002–2004) were used to identify patients ≥40 years 
of age with a diagnosis of type II diabetes concurrent with any combination of the 
following cardiovascular diseases (CVD): hypertension (HYPT), coronary artery 
disease (CAD), and heart failure (HF). We assessed patients use of any appropriate 
diabetes or cardiovascular medication. Proportion of days covered ≥0.8 was used to 
evaluate medication compliance. Disease burden was deﬁned as any emergency or 
inpatient visit. Logistic regressions were used to identify factors associated with disease 
burden in 2004. RESULTS: We identiﬁed 21,740 patients. Fifty-six percent of patients 
ﬁlled both diabetes and cardiovascular medications. When compared to patients with 
comorbid HYPT(51%), those with two CVD conditions HF & CAD(69%) or HYPT 
& CAD(64%) were more likely to ﬁll both diabetes and cardiovascular medications 
(P < 0.0001). Approximately 43% of patients did not ﬁll or were noncompliant with 
appropriate medications. Major signiﬁcant factors associated with disease burden 
included CVD type vs. HYPT: HF & CAD (OR:3.19), HYPT & CAD (OR:1.55), HF 
(OR:2.12), and CAD (OR:2.31); comorbidities (OR:1.94); medications used vs. no 
appropriate medication ﬁlled: ﬁlled both diabetes and cardiovascular medications 
(OR:1.75), ﬁlled only diabetes medication (OR:1.54); noncompliance with medica-
tions vs. compliance with both medications: not ﬁlled or noncompliant (OR:1.75), or 
compliance with only diabetes (OR:1.35) or only cardiovascular medication 
(OR:1.20); two or more cardiovascular medication ﬁlls (OR:1.20). CONCLUSIONS: 
Prevalence of use for both appropriate diabetes and cardiovascular medications was 
low in diabetic patients with comorbid CVD. We identiﬁed multiple risk factors of 
disease burden, primarily those related to condition severity (based on proxy measures 
of comorbidity with two CVD or ﬁlling both diabetes and CVD medications), as well 
as not using or not complying with medications.
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TRENDS IN C-REACTIVE PROTEIN SCREENING PRIOR TO STATIN USE 
IN THE UNITED STATES
Slejko JF, Anderson HD, Valuck RJ
University of Colorado Denver, Aurora, CO, USA
OBJECTIVES: The objective of this study was to explore trends in high sensitivity 
C-reactive protein (hs-CRP) screening prior to statin use, as compared to current lipid 
screening practices. METHODS: The PharMetrics Integrated Outcomes Database was 
used to obtain medical claims records for continuously enrolled adult (≥18 years) 
ﬁrst-time statin users. Patients were followed for one year. Both hs-CRP and lipid tests 
were identiﬁed by CPT-4 procedure codes. Descriptive statistics were used to charac-
terize the population and estimate unadjusted associations between patient character-
istics and hs-CRP testing. Multivariable logistic regression was used to estimate the 
odds of testing, controlling for age, gender, diabetes, statin intensity, prescribing physi-
cian specialty, geographic region and health plan type. RESULTS: Between July 1, 
1997 and March 31, 2007, 33,666 new statin users received lipid tests within 90 days 
prior to the index statin prescription. One thousand (3%) also received hs-CRP tests 
during this time. Over 80% of these individuals received the tests in 2004 or later. 
Those receiving hs-CRP tests were less likely to have a Medicare, Medicaid or other 
type of plan, as compared to private insurance (P < .05) and were less likely to reside 
in the South, Midwest or West, as compared to the Northeast (P < 0.01). Individuals 
who received hs-CRP tests had higher adjusted odds of receiving a high potency statin 
(OR = 1.37, P < .01) and lower odds of having diabetes (OR = 0.56, P < 0.01). Those 
receiving hs-CRP tests were more likely to have a cardiologist as their statin-prescrib-
ing physician, rather than a family or general practitioner (OR = 1.31, P = 0.02). 
CONCLUSIONS: Rates of hs-CRP testing are very low, but higher among those seeing 
a cardiologist or having private insurance. Those who received a high potency statin 
had higher rates of testing, suggesting that those with higher cardiovascular risk may 
be more likely to receive an hs-CRP test.
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THE UTILISATION AND EFFECTIVENESS OF ANTITHROMBOTIC 
AGENTS FOR PREVENTING DEEP VEIN THROMBOSIS AFTER TOTAL 
HIP REPLACEMENT—A CASE STUDY IN SOUTHERN TAIWAN
Yu YY1, Chen LC1, Chien SH2
1Kaohsiung Medical University, Kaohsiung, Taiwan, 2Kaohsiung Medical University Hospital, 
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OBJECTIVES: Antithrombotic therapy is effective in preventing thromboembolic 
diseases, and it has been recommended by several international guidelines to prevent 
deep vein thrombosis (DVT) after major orthopedic surgeries under carefully monitor-
ing bleeding risks. To establish Taiwanese local guidance, this case study aims to 
evaluate the current utilization and effectiveness of antithrombotic agents for prevent-
ing DVT after total hip replacement (THR). METHODS: This one-year retrospective 
cohort study was conducted at a medical center in Southern Taiwan from May 2008 
to April 2009. Adult patients (above 18 years) who had undergone primary THR were 
identiﬁed by inpatient electronic database. Their medical records were reviewed from 
surgery date to three months post-operation for collecting demographic details and 
DVT-related clinical symptoms as the surrogate of effectiveness. Descriptive statistic 
and time-to-event analysis were then conducted. RESULTS: Medical records of 82 
patients (57.32% women) were reviewed. The average age is 59.15 ± 13.43 years and 
the mean body mass index is 25.20 ± 4.86 kg/m2. Only 31 out of the 82 patients 
(37.80%) had ever received prophylactic antithrombotic agents after surgery and all 
of them used aspirin, but only 22 patients used aspirin for more than 10 days. Twelve 
patients presented DVT symptoms after surgery but only one is from prophylactic 
group. Independent relative risk of DVT for patients without prophylaxis is 8.25 folds 
of patients with prophylaxis (95% conﬁdence interval: 1.48, 154.91). DVT symptoms 
mainly (91.67%) occurred within 15 days after THR and the median duration to 
symptoms presentation is 12 days. CONCLUSIONS: Antithrombotic therapy is not 
commonly used to prevent DVT after THR in this medical center. Aspirin alone seems 
effectively reduces the risk of DVT-related symptoms. It is necessary to further inves-
tigate the effectiveness of prophylactic antithrombotic agents after THR from Taiwan-
ese population-based database and explore the potential genetic factors inﬂuencing 
the effectiveness of antithrombotic therapy.
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COMPARATIVE EFFECTIVENESS ANALYSIS IDENTIFIES A SUPERIOR 
POINT OF CARE DEVICE FOR ASSESSING THE INTERNATIONAL 
NORMALIZED RATIO
Shermock KM1, Streiff MB2, Kraus P1, Pinto BL1, Lavallee DM3
1The Johns Hopkins Medical Institutions, Baltimore, MD, USA, 2The Johns Hopkins University 
School of Medicine, Baltimore, MD, USA, 3Lovelace Respiratory Research Institute, Sykesville, 
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OBJECTIVES: Comparative effectiveness research identiﬁes superior clinical devices 
or treatments through head-to-head comparisons. This study describes the use of an 
innovative framework to assess the quality and safety of two INR Point of Care 
devices. METHODS: Patients enrolled in the hematology Anticoagulation Manage-
ment Service provided three INR measures: one venous sample analyzed by our lab 
(considered the standard measure), one ﬁngerstick analyzed by the Hemochron Sig-
nature Elite POC device and another ﬁngerstick by the Coaguchek XS Plus. Agreement 
between INR values from each device and the lab was assessed. Agreement was 
achieved when the INR measures were predicted by a novel, validated method to lead 
to the same clinical decision. Differences in agreement between the POC devices and 
the lab were assessed using McNemar’s test of paired proportions. RESULTS: Ninety-
nine subjects were enrolled into the study. There was signiﬁcantly less difference 
between INR values from the Coaguchek XS device and the lab compared to the 
Hemochron device (average absolute difference = 0.24 vs 0.41 p < 0.05). The Hemo-
chron device tended to report both high and low INR values were within the target 
range when the laboratory said otherwise. Consequently, the Hemochron device was 
signiﬁcantly more likely to lead to a different clinical decision than the core laboratory 
compared to the Coaguchek XS (30% vs. 18%, respectively; RR: 1.7, 95% CI: 1.1–
2.4, P = 0.007). CONCLUSIONS: Comparative effectiveness analysis can provide 
essential information to make informed decisions when selecting medical devices to 
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be utilized in clinical practice. The analytic framework in this comparative effective-
ness analysis demonstrated the Coaguchek XS device to have a signiﬁcantly higher 
level of agreement with the core lab compared to the Hemochron device. This analysis 
led our institution to select the Coaguchek XS for use in our anticoagulation clinics 
on the basis of a superior quality and safety proﬁle.
PCV15
BLOOD PRESSURE GOAL ACHIEVEMENT AMONG HYPERTENSION 
PATIENTS TREATED WITH VALSARTAN-BASED SINGLE PILL 
COMBINATION VS. ARB-BASED FREE COMBINATION IN SOUTH 
CENTRAL REGION
Chang JR1, Yang W1, Fellers TS1, Kahler KH1, Orloff J1, Xie J2, Tsaneva M2, Yu AP2, 
Wu EQ2
1Novartis Pharmaceuticals Corporation Medical, East Hanover, NJ, USA, 2Analysis Group, 
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OBJECTIVES: To compare blood pressure (BP) goal achievement associated with the 
use of valsartan-based single pill combination (SPC) vs. ARB-based free combination 
(FC) among adult hypertension patients in South Central region (TX, AL, MS, LA, 
KS, TN, MO, AR & OK). METHODS: Data were collected from physician-adminis-
tered chart review of adult hypertension patients. All patients had uncontrolled BP 
before initiating one of the index therapies (SPC: valsartan+amlodipine or 
valsartan+HCTZ, FC: ARB+CCB or ARB+HCTZ) between 07/2008 and 06/2009. Up 
to 3 BPs were collected starting from 45 days after the therapy initiation. BP goal was 
<130/80 mmHg for patients with diabetes, chronic renal disease or coronary heart 
disease; or <140/90 mmHg for patients without these comorbidities. Kaplan-Meier 
method with log-rank test was used to compare rates of BP goal achievement associ-
ated with SPC vs. FC over time. Cox proportional hazard models were used to estimate 
the likelihood of BP goal achievement associated with SPC vs. FC, controlling for 
demographics, baseline BP, hypertension history, comorbidities, prior and concurrent 
use of anti-hypertensive medications, and physician specialty. RESULTS: The chart 
review included 813 patients: 415 on SPC (210 valsartan+amlodipine and 205 
valsartan+HCTZ) and 398 on FC (200 ARB+CCB and 198 ARB+HCTZ). In FCs, the 
most commonly used ARB and CCB were valsartan (29.1%) and amlodipine (81.5%), 
respectively. The rates of BP goal achievement were higher among SPC vs. FC patients 
over time (p = 0.007): 30.5% vs. 28.3% at month 3 and 63.4% vs. 53.8% at month 
6. Cox regression conﬁrmed that SPC patients were more likely to achieve BP goal 
(HR = 1.22; p = 0.047). Similar trend was observed in the subgroup analyses compar-
ing SPC valsartan+amlodipine vs. FC ARB+CCB and SPC valsartan+HCTZ vs. FC 
ARB+HCTZ separately. CONCLUSIONS: Patients using valsartan-based SPC were 
more likely to achieve BP goal than those treated with ARB-based FC.
PCV16
AN ASSESSMENT OF OPTIMAL LIPID VALUE ATTAINMENT AND 
ASSOCIATED DYSLIPIDEMIA TREATMENT PATTERNS FROM 2005 TO 
2009 IN A COMMERCIALLY INSURED POPULATION
Tan H1, Yu J1, Bullano M2, Willey VJ3, Cziraky MJ1
1HealthCore, Inc., Wilmington, DE, USA, 2AstraZeneca, Wilmington, DE, USA, 3University of 
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OBJECTIVES: Evidence-based guidelines for dyslipidemia therapy have provided 
deﬁnitive goals for low-density lipoprotein cholesterol (LDL-C) and triglycerides (TG) 
and suggested abnormal values for high-density lipoprotein cholesterol (HDL-C). The 
study objective was to determine lipid value attainment and dyslipidemia treatment 
rates. METHODS: Adult patients with two or more complete lipid panels from 
January 2005 through February 2009, regardless of dyslipidemia therapy, were identi-
ﬁed from the US nationally-representative HealthCore Integrated Research DatabaseTM 
(HIRD). Cardiovascular risk status was assigned based on National Cholesterol Edu-
cation Program (NCEP) criteria. Optimal lipid value (target) attainment was deﬁned 
using NCEP, American Heart Association, and American Diabetes Association crite-
ria. Target attainment for LDL-C, HDL-C and TG and lipid therapy treatment pat-
terns are described. RESULTS: A total of 227,903 patients were identiﬁed (mean 
follow-up = 1.9 years). At index lab, 21.1% of patients were at target for all three 
lipid fractions, 11.9% had no lipid fractions at target, 66.3% were at LDL-C target 
and 63.6% were not at target for either HDL-C or TG. Regardless of initial lipid 
fractions, only 28.7% of patients attained target over follow-up in all three lipid 
fractions. In patients with no lipid fractions at target at index, only 6.8% attained 
target for all lipid fractions and almost a third (31.9%) stayed at no lipid fractions at 
target; 44.4% of patients were receiving lipid-modifying therapy as of the last lipid 
lab (up from 33.0% at index), with twice as many on therapy attaining all targets 
versus no targets (66.6% vs. 29.0%). Statins were the most commonly used therapy 
(35.8%). CONCLUSIONS: Challenges to mixed dyslipidemia therapy still exist as 
evidenced by a minority of patients attaining optimal lipid values during the very 
recent timeframe of this study. These data may serve as valuable baseline benchmarks 
to evaluate the impact of new dyslipidemia guidelines and therapies.
PCV18
COST-UTILITY ANALYSIS OF TWO KINDS OF THERAPY FOR ACUTE 
ISCHEMIC STROKE
Fang Z
Shenyang Pharmaceutical University, Shenyang , Liaoning Provinc, China
OBJECTIVES: Mortality of Stroke in China is highest in the world, having brought 
a heavy ﬁnancial burden to society. And the number of acute Ischemic Stroke 
accounted for 75% of the total cases. This study wants to evaluate the treatment 
program to ﬁnd a better cost effectiveness treatment to offer reference for patients and 
clinicians choosing the right treatment. METHODS: A total of 145 cases with acute 
Ischemic Stroke during a period of 2007 −2008 admitted in 21 hospitals in China 
were divided randomly into two groups. One group of 69 patients was treated by 
Butylphthalide sodium chloride injection and Aspirin, another group of 66 patients 
were treated by Ozagrel injection and Aspirin. Two kinds of therapy were evaluated 
by double-blind, double-dummy trial from patients’ perspective. Utility of patients 
was investigated with EQ-5D.Direct costs were collected from HIS and questionnaires, 
indirect costs were estimated based on the opportunity cost of the time for caring and 
curing. Probabilistic sensitivity analysis using nonparametric Bootstrapping was done. 
RESULTS: From the EQ-5D score we can learn that the improved values of 
Butylphthalide group score during 8–14 days and 15–90 days are higher than that of 
Ozagrel group, the average cost per QALY (Quality-Adjusted Life-year) of a patient 
for Butylphthalide group (RMB 225,753.4) was lower, with RMB 11,706.3, than 
Ozagrel group (RMB 237,459.7), and incremental costs were RMB 451,710.5[95%CI, 
RMB 218,689.55–1080, 313.05]. The acceptability curve generated from the ICUR 
can be seen the possibility of Ozagrel group having the cost –effectiveness advantage 
is zero if the willingness to pay per QALY is lower than RMB 192,000.CONCLU-
SIONS: Switching from the current programmed to Butylphthalide group is more 
cost-effective as compared to Ozagrel group.
PCV19
CLINICAL AND ECONOMIC IMPACT OF A PROGRAM COMBINING 
COMPREHENSIVE LIPID PROFILING WITH A HEART DISEASE 
TREATMENT PROTOCOL
McAna J, Couto J, Goldfarb N
Thomas Jefferson University, Philadelphia, PA, USA
OBJECTIVES: To evaluate the effectiveness of a comprehensive lipoprotein proﬁle 
(VAP) test coupled with an aggressive treatment protocol when compared to a stan-
dard lipid proﬁle test in patients with ischemic heart disease (IHD) or congestive heart 
failure (CHF). METHODS: All WellMed health plan enrollees with a diagnosis of 
IHD or CHF who had continuous enrollment between July 1, 2006 and June 30, 2008 
were identiﬁed. The case group (n = 1767) having at least one VAP test during this 
period was compared with the control group (n = 289) having no lipid testing or 
traditional lipid testing only. Univariate statistics were analyzed to describe the groups, 
and bivariate statistical tests (t-test or chi-square) examined differences between the 
two cohorts. RESULTS: Use of a treatment protocol in conjunction with a VAP test 
resulted in a signiﬁcant decrease in LDL (−6.64 mg/dL, <0.001) as well as an increase 
in HDL (3.95 mg/dL, <0.001). Individuals in the control group saw a signiﬁcant 
decrease in LDL (−6.14 mg/dL, 0.002) but did not see a signiﬁcant change in HDL 
(−1.21 mg/dL, 0.076). Combination drug therapy was more commonly used for cases 
when compared to controls (average drug types 2.1 vs. 1.8, 0.0004); particularly, the 
use of niacin containing products was considerably higher in the case group when 
compared to the control group (36% vs. 14.4%, <0.0001). Mean total costs in year 
1 ($4,308 vs. $5,141, 0.1157) and year 2 ($4,853 vs. $7,413, 0.0255) were lower for 
cases. CONCLUSIONS: Greater utilization of combination therapy guided by the 
VAP test appears to better manage IHD and CHF patients to NHLBI ATP III HDL 
and LDL targets than controls receiving usual care guided by traditional lipid testing. 
Advanced lipid proﬁle tests appear to offer clinicians better information about their 
patients’ lipid abnormalities when compared to traditional testing.
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VENOUS THROMBOEMBOLIC COMPLICATIONS IN BURN PATIENTS 
RECEIVING HEPARIN OR ENOXAPARIN AS PROPHYLAXIS
Bushwitz J1, LeClaire A2, He J3, Mozingo D2
1Barnes-Jewish Hospital, St. Louis, MO, USA, 2Shands at the University of Florida, Gainesville, 
FL, USA, 3University of Florida, Gainesville, FL, USA
OBJECTIVES: To examine the comparative effectiveness of heparin 5000 units given 
subcutaneously twice a day or three times a day, enoxaparin 30 mg given subcutane-
ously twice a day, and enoxaparin 40 mg given subcutaneously daily for the preven-
tion of venous thromboembolism in burn patients. METHODS: A retrospective cohort 
study was conducted by using the hospital claims database. All adult patients were 
included if they were admitted to Shands hospital between January 1, 1998 and 
September 30, 2008, had primary diagnoses of burn, and received either subcutaneous 
heparin or enoxaparin for VTE prophylaxis. The primary outcome was a VTE event, 
which was identiﬁed by using a previously validated ICD-9 coding algorithm and 
further conﬁrmed by chart review for radiographic evidence. RESULTS: A total of 
1111 patients were included. Seven patients (0.63%) experienced VTE events: 5 
(0.83%) received heparin, 1 (0.92%) received enoxaparin 30 mg, and 1 (0.25%) 
received enoxaparin 40 mg. There were no incidences of heparin-induced thrombocy-
topenia identiﬁed in any group. CONCLUSIONS: The VTE incidence is low in burn 
patients receiving pharmacological prophylaxis. Both heparin and enoxaparin appear 
to be equally effective in preventing VTE complications in this patient population.
PCV21
A BENEFIT-RISK ASSESSMENT OF USING CYP2C19 GENOTYPE 
INFORMATION TO GUIDE ANTIPLATELET THERAPY IN PATIENTS 
WITH ACUTE CORONARY SYNDROME
Guzauskas GF1, Veenstra D1, Hughes D2
1University of Washington, Seattle, WA, USA, 2Bangor University, Bangor, UK
OBJECTIVES: To quantitatively assess the potential beneﬁts and harms of using 
reduced-function CYP2C19 genotype information to guide the use of the antiplatelet 
